Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for early refractory immune thrombocytopenia
ACTRN12613000721707Phase 2Completed
- Sponsor
- Alfred Health
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of eltrombopag in immune thrombocytopenia (ITP), sponsored by Alfred Health. Primary endpoint: Overall response rate at Week 12. Started Feb 2014; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ACTRN12613000721707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000721707.